<!DOCTYPE html>
<html>
<head>
<meta charset="utf-8"/>
<meta content="width=device-width, initial-scale=1.0" name="viewport"/>
<link href="../../../webpages.css" rel="stylesheet"/>
</head>
<body>
<div class="banner">
<div class="banner-content">
<h1>DermpathNet</h1>
</div>
</div>
<nav>
<a href="../../../index.html" target="_blank">
<text type="button">Home</text>
</a>
<a href="../../../browser-page-317.html" target="_blank">
<text type="button">Browse</text>
</a>
<a href="../../../download-page.html" target="_blank">
<text type="button">Downloads</text>
</a>
<a href="../../../contact-us.html" target="_blank">
<text type="button">About</text>
</a>
</nav>
<footer class="site-footer">
<p>@2024 New York University Grossman School of Medicine, Weill Cornell Medicine</p>
<!--<p>Privacy Policy | Terms of Service | Cookie Policy</p>-->
</footer>
<title>Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report.-DermPath</title>
<div class="content-container"> <div class="figures-container"> <div class="image-side"> <img alt="Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report." class="clickable-image" src="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7153663/bin/jh-08-132-g001.jpg"/> </div> <div class="text-side"> <h1>Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report.</h1> <p>Primary cutaneous anaplastic large cell lymphoma. A dense, cellular infiltrate fills the dermis (H&amp;E, × 20) (a) comprised of cells with uniform CD30 expression (× 20) (b). The overlying epidermis and follicular epithelium exhibit a reactive pseudoepitheliomatous hyperplasia mimicking squamous cell carcinoma (H&amp;E, × 100) (c). Large, pleomorphic and mitotically active cells with bizarre nuclear contours predominate below the epidermal changes (H&amp;E, × 200) (d). The markedly atypical cells exhibited an immunophenotype consistent with lymphoma. Higher power magnification of CD30 highlighting lesional cells (× 200) (e). The tumor cells were negative for ALK, CD20 and CD56, EBER, cytokeratin, 34BetaE12, and p63 (not shown). H&amp;E: hematoxylin-eosin; ALK: anaplastic lymphoma kinase; EBER: Epstein-Barr virus-encoded small RNA.</p> <p>PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32300458/" target="_blank">32300458</a></p><p>Type: Premalignant/Malignant, Category: Hematolymphoid</p>
</div> </div></div></body></html>